Sjögren syndrome is an autoimmune disorder in which the body's white blood cells attack and destroy other cells. It can exist by itself (primary Sjögren syndrome) or develop in association with another disorder such as rheumatoid arthritis, systemic sclerosis, primary biliary cirrhosis, or Hashimoto thyroiditis (associated Sjögren syndrome). Hallmarks are the dry mouth and dry eyes known as the sicca syndrome . Sjögren syndrome affects 1 million to 4 million people in the United States. Most are over 40 years old at the time of diagnosis. Women are 9 times more likely to have Sjögren syndrome than men. The disease is named after Swedish ophthalmologist (eye physician) Henrik Sjögren (1899-1986), who first described it. The July 28, 2010, issue of JAMA includes an article about treatment of primary Sjögren syndrome.
Although Sjögren syndrome often presents only with the sicca syndrome, symptoms can occur in any part of the body. Dryness of the eyes may severely damage the cornea, resulting in a scratchy or irritated sensation. Lack of tears can cause permanent eye damage. Insufficient saliva can cause cavities and dull taste and smell and make eating and swallowing painful. Dryness of the trachea can result in cough. In one-third of people with Sjögren syndrome, the parotid (salivary) glands become enlarged and tender. One-third of patients may develop joint pain. Lymph nodes throughout the body may enlarge. Nerves, lungs, and other organs may be damaged by inflammation. Debilitating fatigue and pain can impair quality of life.
A sensation of dry mouth and dry eyes with joint inflammation is often sufficient to suspect the diagnosis. Tear production is tested for by the Schirmer test (a filter paper strip is placed inside each lower eyelid for 5 minutes). Ophthalmologists test for damage to the cornea (eye surface) using fluorescein staining. A salivary gland biopsy may be required to confirm the diagnosis. Your doctor may also perform some blood tests or other studies.
Grahic Jump Location
There is no specific treatment for Sjögren syndrome. Treatment of sicca manifestations is mainly symptomatic with saliva substitutes and eyedrops and is typically intended to limit the damage that can result from chronic dryness. Nonsteroidal anti-inflammatory drugs such as ibuprofen may be used to treat musculoskeletal symptoms. People with severe symptoms are treated with steroids or immunosuppressive drugs. New medications such as monoclonal antibodies are under investigation.
Prognosis in Sjögren syndrome varies. Many patients have mild disease, experiencing only dry eyes and mouth; others go through cycles of good health followed by severe disease. At any time, disease activity can remain stable, worsen, or go into remission. People with Sjögren syndrome have a higher rate of B-cell lymphoma; those with severe disease are more likely to develop lymphoma. Overall, 5% of people with Sjögren syndrome develop some form of malignancy.
National Institute of Neurological Disorders and Strokehttp://www.ninds.nih.gov/disorders/sjogrens
Sjögren Syndrome Foundationhttp://www.sjogrens.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish.
Sources: National Institute of Neurological Disorders and Stroke, Sjögren Syndrome Foundation
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.
TOPIC: AUTOIMMUNE DISORDERS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.